Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click on 'Find out more' to see our Cookie statement.

OxSyBio, an Oxford University biotech spinout company developing 3D printer technology capable of printing biological materials with a diverse range of therapeutic purposes, has secured £10m in Series A financing from Woodford Investment Management alongside new and existing backers.

A 3D printed droplet © Oxford University/G Villar

OxSyBio has a unique 3D printing platform which enables it to assemble the building blocks of life. The synthetic biology company's ultimate ambition is to fabricate therapeutic tissues for patients using living cells or non-living 'artificial' cells, or hybrid materials.

These tissues have the potential to revolutionise the growing field of regenerative medicine, allowing for the literal printing of new tissues that can be used to repair or replace parts of the body damaged through disease or injury.

OxSyBio, which is underpinned by research conducted in the lab of Professor Hagan Bayley, the founding academic behind Oxford Nanopore Technologies, was spun out from Oxford University’s Department of Chemistry by the institution’s innovation arm Oxford University Innovation in 2014.

The Series A – the name typically given to a company's first significant round of venture capital financing – was led by Woodford Investment Management, with participation from IP Group plc and Parkwalk Advisors Ltd. The round, part of which is subject to the achievement of milestones, builds on the previous £1m seed funding, bringing OxSyBio's total fundraising to date to £11m. The latest investment will enable the company to further develop its artificial cell platform and 3D bioprinting technology to develop disruptive products that harness the power of biology for impact in medicine.

Dr Hadrian Green, CEO of OxSyBio, said: 'Biological functions are difficult to create using electrical or mechanical devices, therefore harnessing the power of biological materials in non-living devices will be highly disruptive. This investment is testament to the power of the original ideas and the hard work of our Chief Technology Officer Sam Olof, the OxSyBio team and the founding lab to turn research into reality. OxSyBio wishes to pay tribute to Oxford University and the unique culture of patient capital, pioneered by Neil Woodford and IP Group, which is instrumental to delivering long-term transformational technologies.'

Moray Wright, Chief Executive Officer at Parkwalk Advisors, said: 'The 3D printing of tissues from living cells in high-throughput formats is already proving interesting to academic and pharmaceutical research teams, with massive potential impact right across the board. The concept of artificial cells has had a long history, but with OxSyBio's platform technology, the concept is becoming a reality.'

Professor Hagan Bayley added: 'This deal provides the long-term capital required to deliver our ambition of building affordable tissues for patients. The company has already made important strides in translating this technology into a real world product, and we look forward to continuing our close research collaboration.'

Story courtesy of the University of Oxford News Office

Similar stories

Oxford University Innovation announces Mairi Gibbs as its new COO

Dr Mairi Gibbs, formerly Head of Operations at Oxford University Innovation (OUI), has been promoted to Chief Operating Officer at OUI, taking the reins from the outgoing Dr Adam Stoten.

Project championing cleaner energy production announced

The Energy Systems Accelerator pilot (Mini TESA), to be based at Osney Mead in Oxford, is a world-leading multi-disciplinary hub, championing green innovation

International collaboration sheds light on the mechanism of magnetic sensing in birds

A collaboration of biologists, chemists and physicists from the Universities of Oxford (UK) and Oldenburg (Germany) have been accumulating evidence that the magnetic sense in night migratory birds, such as the European robin, is based on a specific light‐sensitive protein in the eye.

Professor Kylie Vincent appointed first Academic Champion for Women in Entrepreneurship

This is a new post, which will work in support of the priorities in the University Strategic Plan 2018-2023 and the Knowledge Exchange Strategy, around innovation and entrepreneurship.

Major academic-industry collaboration to tackle global challenges in sustainability

The University of Oxford joins a major new collaboration with academia and industry to use sustainable chemical technologies to accelerate the UK’s transition to net zero carbon emissions.

Oxford University and Prenetics announce landmark collaboration to scale rapid testing tech globally

Today, the University of Oxford, Prenetics Limited, a global leader in diagnostics and genetic testing, and Oxford Suzhou Centre for Advanced Research (OSCAR) have signed collaboration agreements to further develop the award-winning OxLAMP technology, a rapid, molecular testing technology for infectious diseases.